

Manuela Mollejo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/314794/publications.pdf>

Version: 2024-02-01

109
papers

6,426
citations

46918

47
h-index

69108

77
g-index

110
all docs

110
docs citations

110
times ranked

8214
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic and phenotypic attributes of splenic marginal zone lymphoma. <i>Blood</i> , 2022, 139, 732-747.	0.6	49
2	Mastocytosis in the skin accompanied by pseudo-Kaposi's sarcoma. <i>Journal of Dermatology</i> , 2021, 48, 657-660.	0.6	1
3	Epigenetic Deregulation of the Histone Methyltransferase KMT5B Contributes to Malignant Transformation in Glioblastoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 671838.	1.8	6
4	Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers. <i>Blood Advances</i> , 2021, 5, 5588-5598.	2.5	24
5	Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma. <i>Scientific Reports</i> , 2021, 11, 1886.	1.6	25
6	Epigenetic downregulation of TET3 reduces genome-wide 5hmC levels and promotes glioblastoma tumorigenesis. <i>International Journal of Cancer</i> , 2020, 146, 373-387.	2.3	45
7	Simultaneous occurrence of cutaneous mastocytosis and juvenile xanthogranuloma in a child: Random or true association?. <i>Pediatric Dermatology</i> , 2020, 37, 716-720.	0.5	0
8	TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors. <i>Neuro-Oncology Advances</i> , 2020, 2, vdz059.	0.4	20
9	Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma. <i>PLoS ONE</i> , 2019, 14, e0212813.	1.1	31
10	Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma. <i>British Journal of Haematology</i> , 2018, 183, 497-501.	1.2	17
11	Spontaneously Ruptured Spleen Samples in Patients With Infectious Mononucleosis. <i>American Journal of Clinical Pathology</i> , 2018, 150, 310-317.	0.4	10
12	Molecular Study of Long-Term Survivors of Glioblastoma by Gene-Targeted Next-Generation Sequencing. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 710-716.	0.9	31
13	Loss of 5hmC identifies a new type of aberrant DNA hypermethylation in glioma. <i>Human Molecular Genetics</i> , 2018, 27, 3046-3059.	1.4	26
14	p-MAPK1 expression associated with poor prognosis in angioimmunoblastic T-cell lymphoma patients. <i>British Journal of Haematology</i> , 2017, 176, 661-664.	1.2	2
15	Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations. <i>Blood</i> , 2017, 129, 1042-1045.	0.6	52
16	Splenic marginal zone lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 56-64.	0.7	33
17	Clinical and diagnostic relevance of NOTCH2 and KLF2 mutations in splenic marginal zone lymphoma. <i>Haematologica</i> , 2017, 102, e310-e312.	1.7	31
18	Comment on: "A Unique Clinicopathological Manifestation of Fungal Infection: A Case Series of Deep Dermatophytosis in Immunosuppressed Patients". <i>American Journal of Clinical Dermatology</i> , 2017, 18, 709-711.	3.3	3

#	ARTICLE	IF	CITATIONS
19	Erythema multiforme-like reaction resulting from vitamin K ₁ oxide (phytomenadione) Tj ETQq1 1 0.784314 rgBT /Over	0.8	11
20	Shared Oncogenic Pathways Implicated in Both Virus-Positive and UV-Induced Merkel Cell Carcinomas. Journal of Investigative Dermatology, 2017, 137, 197-206.	0.3	78
21	Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 <i>KIT</i> mutations and review of the literature. Oncotarget, 2017, 8, 68950-68963.	0.8	83
22	Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. Oncotarget, 2016, 7, 18036-18049.	0.8	26
23	Antineutrophil cytoplasmic antibody negative pauci-immune extracapillary glomerulonephritis. Nephrology, 2016, 21, 301-307.	0.7	7
24	Intravascular large B-cell lymphoma in a kidney biopsy. Blood, 2016, 127, 2939-2939.	0.6	3
25	C-MYC is related to GATA3 expression and associated with poor prognosis in nodal peripheral T-cell lymphomas. Haematologica, 2016, 101, e336-e338.	1.7	25
26	Diagnosis and classification of mastocytosis in non-specialized versus reference centres: a Spanish Network on Mastocytosis (REMA) study on 122 patients. British Journal of Haematology, 2016, 172, 56-63.	1.2	15
27	Glomerular C3d as a novel prognostic marker for renal vasculitis. Human Pathology, 2016, 56, 31-39.	1.1	31
28	An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors. Clinical Cancer Research, 2016, 22, 2032-2040.	3.2	17
29	Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. Journal of Allergy and Clinical Immunology, 2016, 137, 168-178.e1.	1.5	72
30	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. Blood, 2015, 125, 1922-1931.	0.6	53
31	Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activation. Haematologica, 2015, 100, e200-e203.	1.7	21
32	MYD88 (L265P) Somatic Mutation in Marginal Zone B-cell Lymphoma. American Journal of Surgical Pathology, 2015, 39, 644-651.	2.1	76
33	Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients. Journal of Neuro-Oncology, 2015, 122, 441-450.	1.4	41
34	Molecular Classification Defines 4 Prognostically Distinct Glioma Groups Irrespective of Diagnosis and Grade. Journal of Neuropathology and Experimental Neurology, 2015, 74, 241-249.	0.9	38
35	Secretory meningioma with KLF4 K409Q mutation in collision with glioma. , 2015, 34, 322-329.		14
36	PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases. PLoS ONE, 2014, 9, e112148.	1.1	18

#	ARTICLE	IF	CITATIONS
37	NF κ B expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. <i>Modern Pathology</i> , 2014, 27, 1331-1337.	2.9	27
38	Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use. <i>Leukemia and Lymphoma</i> , 2014, 55, 929-931.	0.6	40
39	Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas. <i>British Journal of Haematology</i> , 2014, 164, 896-899.	1.2	0
40	Hepatitis C virus-related lymphoproliferative disorders encompass a broader clinical and morphological spectrum than previously recognized: a clinicopathological study. <i>Modern Pathology</i> , 2014, 27, 281-293.	2.9	22
41	The RHOA G17V gene mutation occurs frequently in peripheral T-cell lymphoma and is associated with a characteristic molecular signature. <i>Blood</i> , 2014, 123, 2893-2894.	0.6	53
42	Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 520-528.e5.	1.5	118
43	CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. <i>Histopathology</i> , 2013, 63, 780-787.	1.6	77
44	Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors. <i>Acta Neuropathologica</i> , 2013, 126, 277-289.	3.9	49
45	Gene expression changes associated with erlotinib response in glioma cell lines. <i>European Journal of Cancer</i> , 2013, 49, 1641-1653.	1.3	35
46	Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis. <i>Annals of Allergy, Asthma and Immunology</i> , 2013, 111, 425-426.	0.5	33
47	Splenic marginal zone lymphoma: comprehensive analysis of gene expression and miRNA profiling. <i>Modern Pathology</i> , 2013, 26, 889-901.	2.9	45
48	Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas. <i>Haematologica</i> , 2013, 98, 57-64.	1.7	33
49	EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor- κ B activation. <i>Modern Pathology</i> , 2012, 25, 968-982.	2.9	172
50	Complete Response After Imatinib Mesylate Therapy in a Patient With Well-Differentiated Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2012, 30, e126-e129.	0.8	59
51	Genetic Alterations Associated With Progression and Recurrence in Meningiomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 882-893.	0.9	47
52	Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. <i>British Journal of Haematology</i> , 2012, 159, 164-171.	1.2	81
53	High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal zone lymphoma. <i>British Journal of Haematology</i> , 2012, 158, 712-726.	1.2	45
54	Nodal marginal zone lymphoma: gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targets. <i>Blood</i> , 2012, 119, e9-e21.	0.6	91

#	ARTICLE	IF	CITATIONS
55	Hairy cell leukemia, blastic type: description of spleen morphology and immunophenotype of a distinctive case. <i>Leukemia and Lymphoma</i> , 2011, 52, 1589-1592.	0.6	3
56	Evaluation of the WHO criteria for the classification of patients with mastocytosis. <i>Modern Pathology</i> , 2011, 24, 1157-1168.	2.9	89
57	Marginal zone lymphoma. <i>Seminars in Diagnostic Pathology</i> , 2011, 28, 135-145.	1.0	15
58	Molecular Characterization of the Region 7q22.1 in Splenic Marginal Zone Lymphomas. <i>PLoS ONE</i> , 2011, 6, e24939.	1.1	23
59	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , 2011, 117, 1595-1604.	0.6	173
60	miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. <i>Blood</i> , 2011, 118, 1034-1040.	0.6	90
61	Hairy cell leukemia variant. <i>Journal of Hematopathology</i> , 2011, 4, 13-16.	0.2	2
62	Improved demonstration of immunohistochemical prognostic markers for survival in follicular lymphoma cells. <i>Modern Pathology</i> , 2011, 24, 698-707.	2.9	9
63	Plk5, a Polo Box Domain-Only Protein with Specific Roles in Neuron Differentiation and Glioblastoma Suppression. <i>Molecular and Cellular Biology</i> , 2011, 31, 1225-1239.	1.1	99
64	Stimulation of ALK by the growth factor midkine renders glioma cells resistant to autophagy-mediated cell death. <i>Autophagy</i> , 2011, 7, 1071-1073.	4.3	27
65	Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features. <i>Haematologica</i> , 2010, 95, 1122-1129.	1.7	79
66	Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. <i>Blood</i> , 2010, 116, 1479-1488.	0.6	174
67	A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. <i>Blood</i> , 2010, 116, e12-e17.	0.6	47
68	Intrafollicular neoplasia/in situ follicular lymphoma: review of a series of 13 cases. <i>Histopathology</i> , 2010, 56, 658-662.	1.6	66
69	Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. <i>British Journal of Haematology</i> , 2010, 151, 435-439.	1.2	20
70	Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas. <i>Neuro-Oncology</i> , 2010, 12, 1278-1290.	0.6	54
71	Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. <i>Haematologica</i> , 2010, 95, 1342-1349.	1.7	128
72	Microarray-Based Comparative Genomic Hybridization (Array-CGH) as a Useful Tool for Identifying Genes Involved in Glioblastoma (GB). <i>Methods in Molecular Biology</i> , 2010, 653, 35-45.	0.4	8

#	ARTICLE	IF	CITATIONS
73	Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 1269-1278.e2.	1.5	263
74	Worse Outcome in Primary Glioblastoma Multiforme With Concurrent Epidermal Growth Factor Receptor and p53 Alteration. <i>American Journal of Clinical Pathology</i> , 2009, 131, 257-263.	0.4	75
75	Primary Cutaneous CD4+ Small/Medium-sized Pleomorphic T-cell Lymphoma Expresses Follicular T-cell Markers. <i>American Journal of Surgical Pathology</i> , 2009, 33, 81-90.	2.1	226
76	Splenic Follicular Lymphoma. <i>American Journal of Surgical Pathology</i> , 2009, 33, 730-738.	2.1	41
77	Novel Genomic Alterations and Mechanisms Associated With Tumor Progression in Oligodendroglioma and Mixed Oligoastrocytoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 274-285.	0.9	13
78	Identification of survival-related genes of the phosphatidylinositol 3-kinase signaling pathway in glioblastoma multiforme. <i>Cancer</i> , 2008, 112, 1575-1584.	2.0	67
79	Comparative genome profiling across subtypes of low-grade B-cell lymphoma identifies type-specific and common aberrations that target genes with a role in B-cell neoplasia. <i>Haematologica</i> , 2008, 93, 670-679.	1.7	77
80	Somatic hypermutation signature in B-cell low-grade lymphomas. <i>Haematologica</i> , 2008, 93, 1186-1194.	1.7	11
81	Identification of novel candidate target genes in amplicons of Glioblastoma multiforme tumors detected by expression and CGH microarray profiling. <i>Molecular Cancer</i> , 2006, 5, 39.	7.9	108
82	BCR gene disruption in a pilomyxoid astrocytoma. <i>Neuropathology</i> , 2006, 26, 442-446.	0.7	23
83	Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. <i>Blood</i> , 2005, 106, 1831-1838.	0.6	138
84	Nodal and splenic marginal zone B cell lymphomas. <i>Hematological Oncology</i> , 2005, 23, 108-118.	0.8	54
85	Expression of the NF- κ B targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. <i>Journal of Pathology</i> , 2005, 206, 123-134.	2.1	126
86	Variability in the Degree of Expression of Phosphorylated I κ B α in Chronic Lymphocytic Leukemia Cases With Nodal Involvement. <i>Clinical Cancer Research</i> , 2004, 10, 6796-6806.	3.2	35
87	Expression Profiling of T-Cell Lymphomas Differentiates Peripheral and Lymphoblastic Lymphomas and Defines Survival Related Genes. <i>Clinical Cancer Research</i> , 2004, 10, 4971-4982.	3.2	88
88	Building an Outcome Predictor Model for Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2004, 164, 613-622.	1.9	87
89	Aberrant Bcl6 Protein Expression in Mantle Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1051-1056.	2.1	55
90	Development of a Real-Time Reverse Transcription Polymerase Chain Reaction Assay for c-myc Expression That Allows the Identification of a Subset of c-myc+ Diffuse Large B-Cell Lymphoma. <i>Laboratory Investigation</i> , 2003, 83, 143-152.	1.7	17

#	ARTICLE	IF	CITATIONS
91	Nodal Marginal Zone Lymphoma: A Heterogeneous Tumor. American Journal of Surgical Pathology, 2003, 27, 762-771.	2.1	106
92	Large B-cell Lymphoma Presenting in the Spleen. American Journal of Surgical Pathology, 2003, 27, 895-902.	2.1	50
93	Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood, 2003, 101, 681-689.	0.6	224
94	Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood, 2003, 101, 4042-4046.	0.6	121
95	The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Research, 2003, 63, 8226-32.	0.4	130
96	Analysis of the IgVH somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood, 2002, 99, 1299-1304.	0.6	158
97	A Short Mutational Hot Spot in the First Intron of BCL-6 Is Associated with Increased BCL-6 Expression and with Longer Overall Survival in Large B-Cell Lymphomas. American Journal of Pathology, 2002, 160, 1371-1380.	1.9	47
98	Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood, 2002, 100, 1648-1654.	0.6	184
99	Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood, 2002, 100, 1648-54.	0.6	45
100	Unique Phenotypic Profile of Monocytoid B Cells. American Journal of Pathology, 2001, 158, 1363-1369.	1.9	27
101	Novel Genomic Imbalances in B-Cell Splenic Marginal Zone Lymphomas Revealed by Comparative Genomic Hybridization and Cytogenetics. American Journal of Pathology, 2001, 158, 1843-1850.	1.9	88
102	Progression to Large B-Cell Lymphoma in Splenic Marginal Zone Lymphoma. American Journal of Surgical Pathology, 2001, 25, 1268-1276.	2.1	126
103	Cutaneous Presentation of Follicular Lymphomas. Modern Pathology, 2001, 14, 913-919.	2.9	29
104	Splenic marginal zone lymphoma with increased number of blasts: An aggressive variant?. Human Pathology, 1999, 30, 1153-1160.	1.1	50
105	7q31-32 Allelic Loss Is a Frequent Finding in Splenic Marginal Zone Lymphoma. American Journal of Pathology, 1999, 154, 1583-1589.	1.9	154
106	Frequent involvement of chromosomes 1, 3, 7 and 8 in splenic marginal zone B-cell lymphoma. British Journal of Haematology, 1997, 98, 446-449.	1.2	56
107	Monocytoid B Cells. American Journal of Surgical Pathology, 1994, 18, 1131-1139.	2.1	35
108	P53 protein expression in lymphomas and reactive lymphoid tissue. Journal of Pathology, 1992, 166, 235-241.	2.1	97

#	ARTICLE	IF	CITATIONS
109	Cranial fasciitis of childhood with reactive periostitis. World Neurosurgery, 1990, 33, 146-149.	1.3	27